After months of delays, a Senate hearing, and a percipitous stock fall, Valeant Pharmaceuticals finally filed their annual 10-k report to the SEC Friday morning.
The document has been delayed multiple times as the comapny reviewed financial documents related to a speacialty pharmacy, Philaor, associated with the company.
The company originally delayed the filing on March 21, stating they had created an ad hoc committee to review Valeant’s financial statements.
The committe then annouced they had completed their review on April 5.
More to come…